Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

Conventional fractionation should not be the standard of care for T2 glottic cancer

Authors: Lynne M. Dixon, Catriona M. Douglas, Shazril Imran Shaukat, Kate Garcez, Lip Wai Lee, Andrew J. Sykes, David Thomson, Nicholas J. Slevin

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to report outcomes and late toxicity following hypofractionated accelerated radiotherapy for T2 glottic cancers. We highlight the importance of hypofractionated treatments with shorter overall treatment times, in improving outcomes for T2 glottic cancers. We also compare the biologically effective dose of hypofractionated regimes, with conventional fractionation.

Methods

One hundred twelve patients with T2 glottic cancer were treated between January 1999 and December 2005. All patients were prescribed a hypofractionated accelerated radiotherapy dose of 52.5 Gray in 3.28 Gray per fraction, delivered over 22 days. Radiobiological calculations were used to assess the relationship of fraction size and overall treatment time on local control outcomes and late toxicity.

Results

The 5-year overall survival was 67%, the 5-year local control was 82%, and the 5-year disease-specific survival was 90%. The respective 5-year local control for T2a and T2b disease was 88.8 and 70.8% (p = 0.032). Severe late toxicity occurred in two patients (1.8%). Radiobiological calculations showed an increase in local control of nearly 12%, with a 10 Gray increase in biologically effective dose.

Conclusion

This study has demonstrated that accelerated hypofractionated regimes have improved local control and similar late toxicity compared with conventional fractionation schedules. This supports the use of hypofractionated regimes as the standard of care for early glottic laryngeal cancers.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
2.
Dey P, Arnold D, Wight R, Kelly CG, MacKenzie K. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev. 2002;(2):CD002027. doi:10.​1002/​14651858.​CD002027.
3.
Vilaseca I, Huerta P, Blanch JL, Fernandez-Planas AM, Jimenez C, Bernal-Sprekelsen M. Voice quality after CO2 laser cordectomy—what can we really expect? Head Neck. 2008;30:43–9.CrossRefPubMed
4.
Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1–T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19:4029–36.CrossRefPubMed
5.
Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane T, Gullane P, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347–53.CrossRefPubMed
6.
Jorgensen K, Godballe C, Hansen O, Bastholt L. Cancer of the larynx—treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol. 2002;41:69–76.CrossRefPubMed
7.
Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK. Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys. 2003;55:322–8.CrossRefPubMed
8.
Frata P, Cellai E, Magrini SM, Bonetti B, Vitali E, Tonoli S, et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys. 2005;63:1387–94.CrossRefPubMed
9.
Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(2):461–6.CrossRefPubMed
10.
Ermiş E, Teo M, Dyker KE, Fosker C, Sen M, Prestwich RJD. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. Radiat Oncol. 2015;10:203.CrossRefPubMedPubMedCentral
11.
12.
Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009. p. 41.
13.
Slevin NJ, Vasanthan S, Dougal M. Relative clinical influence of tumor dose versus dose per fraction on the occurrence of late normal tissue morbidity following larynx radiotherapy. Int J Radiat Oncol Biol Phys. 1993;25(1):23–8.CrossRefPubMed
14.
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. 2009. NIH publication # 09-7473.
15.
Motegi A, Kawashima M, Arahira S, Zenda S, Toshima M, Onozawa M, et al. Accelerated radiotherapy for T1 to T2 glottic cancer. Head Neck. 2015;37(4):579–84.CrossRefPubMed
16.
Berwouts D, Swimberghe M, Duprez F, Boterberg T, Bonte K, Deron P, et al. Intensity-modulated radiotherapy for early-stage glottic cancer. Head Neck. 2016;38(S1):E179–84.CrossRefPubMed
17.
Trotti A, Zhang Q, Bentzen SM, Emami B, Hammond ME, Jones CU, et al. Randomized Trial of Hyperfractionation versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512). Int J Radiat Oncol Biol Phys. 2014;89(5):958–63.CrossRefPubMedPubMedCentral
18.
Howell-Burke D, Peters LJ, Goepfert H, Oswald MJ. T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. Arch Otolaryngol Head Neck Surg. 1990;116:830–5.CrossRefPubMed
19.
Eskiizmir G, Baskın Y, Yalçın F, Ellidokuz H, Ferris RL. Risk factors for radiation failure in early-stage glottic carcinoma: a systematic review and meta-analysis. Oral Oncol. 2016;62:90–100.CrossRefPubMed
20.
Jones TM, De M, Foran B, Harrington K, Mortimore S. Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S75–82.CrossRefPubMedPubMedCentral
21.
National Institute for Health and Care Excellence (2016) Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. NICE guideline (NG36).
22.
Barbosa MM, Araújo VJ Jr, Boasquevisque E, Carvalho R, Romano S, Lima RA, et al. Anterior vocal commissure invasion in laryngeal carcinoma diagnosis. Laryngoscope. 2005;115(4):724–30.CrossRefPubMed
23.
Champion GA, Piccirillo JF. The impact of computed tomography on pretherapeutic staging in patients with laryngeal cancer: demonstration of the will Rogers’ phenomenon. Head Neck. 2004;26(11):972–6.CrossRefPubMed
24.
Lyhne NM, Primdahl H, Kristensen CA, Andersen E, Johansen J, Andersen LJ, et al. The DAHANCA 6 randomized trial: effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. Radiother Oncol. 2015;117(1):91–8.CrossRefPubMed
25.
Fowler JF. A review: the linear quadratic formula and progress in fractionated radiotherapy. Br J Radiology. 1989;62:679–94.CrossRef
26.
Slevin NJ, Hendry JH, Roberts SA, Agren-Cronqvist A. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol. 1992;24(4):215–20. Erratum in: Radiother Oncol. 1992;25(3):227CrossRefPubMed
27.
Taylor JM, Withers HR, Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol. 1990;17:95–102.CrossRefPubMed
28.
Wylie JP, Sen M, Swindell R, Sykes AJ, Farrington WT, Slevin NJ. Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome. Radiother Oncol. 1999;53:15–21.CrossRefPubMed
29.
Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. Radiother Oncol. 2003;68(2):105–11.CrossRefPubMed
30.
Cheah NL, Lupton S, Marshall A, Hartley A, Glaholm J. Outcome of T1N0M0 squamous cell carcinoma of the larynx treated with short-course radiotherapy to a total dose of 50 Gy in 16 fractions: the Birmingham experience. Clin Oncol (R Coll Radiol). 2009;21(6):494–501.CrossRef
31.
Dinshaw KA, Sharma V, Agarwal JP, Ghosh S, Havaldar R. Radiation therapy in T1–T2 glottic carcinoma: influence of various treatment parameters on local control/complications. Int J Radiat Oncol Biol Phys. 2000;48(3):723–35.CrossRefPubMed
32.
Fein DA, Mendenhall WM, Parsons JT, Million RR. T1–T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys. 1993;25:605–11.CrossRefPubMed
33.
Bhateja P, Ward MC, Hunter GH, Greskovich JF, Reddy CA, Nwizu TI, et al. Impaired vocal cord mobility in T2N0 glottic carcinoma: suboptimal local control with radiation alone. Head Neck. 2016;38:1832–6.CrossRefPubMed
34.
Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Ninomiya H, Chikamatsu K, et al. Radiation therapy for T2N0 laryngeal cancer: a retrospective analysis for the impact of concurrent chemotherapy for local control. Int J Radiat Oncol Biol Phys. 2006;64(4):995–1001.CrossRefPubMed
35.
Hirasawa N, Itoh Y, Naganawa S, Ishihara S, Suzuki K, Koyama K, et al. Multi-institutional analysis of early glottic cancer from 2000 to 2005. Radiat Oncol. 2012;7:122.CrossRefPubMedPubMedCentral
36.
Warner L, Chudasama J, Kelly CG, Loughran S, McKenzie K, Wight R, Dey P. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Databse Syst Rev. 2014;12:Art No.: CD002027.
37.
Ansarin M, Cattaneo A, De Benedetto L, Zorzi S, Lombardi F, Alterio D, et al. Retrospective analysis of factors influencing oncologic outcome in 590 patients with early-intermediate glottic cancer treated by transoral laser microsurgery. Head Neck. 2017;39(1):71–81.CrossRefPubMed
38.
Grant DG, Salassa JR, Hinni ML, Pearson BW, Hayden RE, Perry WC. Transoral laser microsurgery for untreated glottic carcinoma. Otolaryngol Head Neck Surg. 2007;137:482–6.CrossRefPubMed
39.
Spielmann PM, Majumdar S, Morton RP. Quality of life and functional outcomes in the management of early glottis carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery. Clin Otolaryngol. 2010;35:373–82.CrossRefPubMed
40.
Bradley PJ, Mackenzie K, Wright R, Pracy P, Paleri V. Consensus statement on management in the UK: transoral laser assisted microsurgical resection of early glottis cancer. Clin Otolaryngol. 2009;34:367–73.CrossRefPubMed
41.
Karasawa K, Kunogi H, Hirai T, Hoji H, Hirowatari H, Izawa H, et al. Radiotherapy with fraction size of 2.25Gy in T1–2 laryngeal and hypopharyngeal cancer. J Radiat Res. 2013;54:684–9.CrossRefPubMedPubMedCentral
Metadata
Title
Conventional fractionation should not be the standard of care for T2 glottic cancer
Authors
Lynne M. Dixon
Catriona M. Douglas
Shazril Imran Shaukat
Kate Garcez
Lip Wai Lee
Andrew J. Sykes
David Thomson
Nicholas J. Slevin
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0915-8

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue

Research

A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study

Research

Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

Research

Expert consensus on re-irradiation for recurrent glioma

Correction

Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old

Research

Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma

Research

Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy